Mereo BioPharma Group plc Presentation at Shares Spotlight Evening
January 23 2017 - 2:05AM
RNS Non-Regulatory
TIDMMPH
Mereo BioPharma Group plc
23 January 2017
Mereo BioPharma Group plc
("Mereo" or the "Company" or the "Group")
Mereo BioPharma to present at the Shares Spotlight Evening in
London on 24 January 2017
London, 23 January 2017 - Mereo BioPharma Group plc (AIM: MPH),
a clinical stage, UK-based, biopharmaceutical company focused on
rare and specialty diseases, is pleased to announce that Chief
Executive Officer, Denise Scots-Knight will be presenting at the
Shares Spotlight Evening on 24 January 2017.
The event will take place at the Novotel Tower Bridge, 10 Pepys
Street, London EC3N 2NR. Registration begins at 18.00 and
presentations at 18.30.
For Further Enquiries:
Mereo BioPharma Group
plc +44 (0)333 023 7319
Denise Scots-Knight, Chief
Executive Officer
Nominated Adviser and
Joint Broker
Cantor Fitzgerald Europe +44 (0)20 7894 7000
Phil Davies
Will Goode
Joint Broker
RBC Capital Markets +44 (0)20 7653 4000
Rupert Walford
Public Relations Adviser
to Mereo Biopharma
FTI Consulting +44 (0)20 3727 1000
Ben Atwell
Simon Conway
Brett Pollard
About Mereo
Mereo is a UK-based biopharmaceutical company focused on the
development of innovative medicines that aim to address unmet
medical needs in rare and specialty disease areas and improve
patient quality of life. The Company seeks to selectively acquire
development-stage product candidates with demonstrated clinically
meaningful data from large pharmaceutical companies and to rapidly
progress these product candidates to subsequent value inflection
points.
Mereo combines the operational discipline and efficiency of a
small company with the financial resources to conduct comprehensive
clinical studies. The Company has the option to directly
commercialise products, for example in orphan diseases, in addition
to partnering or divesting its products.
Mereo's initial portfolio consists of three mid-late stage
clinical assets that were acquired from Novartis in July 2015.
BPS-804 is being developed for the prevention of fractures
resulting from osteogenesis imperfecta (brittle bone disease);
acumapimod (BCT-197), is being developed to treat inflammation in
patients with an AECOPD; and BGS-649 is a once-weekly pill to
restore normal testosterone levels in men with hypogonadotropic
hypogonadism.
In H1 2016 the Company initiated a Phase 2 study with acumapimod
and a Phase 2b study with BGS-649. Mereo expects to commence the
first pivotal trial for BPS-804 during H1 2017. Additional product
opportunities, from a range of large pharmaceutical and
biotechnology companies, are under active evaluation.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAXFAASSXEFF
(END) Dow Jones Newswires
January 23, 2017 02:05 ET (07:05 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024